Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Dermata Therapeutics Inc
Healthcare
P/NCAV
0.16x
Ticker
DRMA
Exchange
NASDAQ
Country
United States
Close
0.34 $
Mkt Cap
993418 $
EV
-6.4M $
NCAV Burn Rate
-5.5%
Current Ratio
4.91
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.8x
EV/FCF
1.0x
Dilution
53.9% p.A
Total Net Income
-33.3M $
Cheapness
20.0%
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average